Evaxion Announces 89% Vaccine Target Precision and Sustained T-Cell and Clinical Responses at Three-Year Follow-Up in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion A/S reported new three-year immune and clinical outcome data for its personalized cancer vaccine EVX-01 in patients with advanced melanoma. In the phase 2 trial, EVX-01 induced an immune response in all patients; the article text cuts off after stating “89% of its personalised vacci…,” so the remainder of that result and further clinical outcomes are unavailable.